Bomedemstat

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-04-02 — Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Class context: a separate phase I/II trial (trial-early) is testing another LSD1 inhibitor, seclidemstat, combined with azacitidine in MDS/CMML — broadens the LSD1-inhibitor development landscape adjacent to the bomedemstat MPN program. (novelty: 3)
• 2026-02-20 — Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis: Phase 2 trial (trial-early) evaluating bomedemstat added to momelotinib in myelofibrosis patients with suboptimal response to momelotinib monotherapy or baseline cytopenias — first prospective test of LSD1 inhibition layered onto JAK inhibition in MF. (novelty: 4)
• 2026-04-23 — A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006): MK-3543-006 (Phase 3 RCT, trial-late): superiority trial of bomedemstat vs best available therapy in HU-resistant/intolerant ET, with primary endpoint of durable clinicohematologic response — second-line companion to the first-line MK-3543-007 trial. (novelty: 3)
• 2026-04-23 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007): MK-3543-007 (Phase 3 RCT, trial-late): head-to-head superiority trial of bomedemstat vs hydroxyurea in cytoreductive therapy-naïve ET, with primary endpoint of durable clinicohematologic response — first first-line challenge of HU by an LSD1 inhibitor. (novelty: 4)

Open questions

Related